Other languages Moberg Pharma AB

Equities

MOB

SE0020353928

Delayed Nasdaq Stockholm Other stock markets 10:02:11 2024-05-14 EDT			5-day change	1st Jan Change
28 ^SEK	+0.50%		-27.50%	+84.21%

05-07	Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-06	Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07
Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure	05-06
Moberg Pharma AB Announces Launch Update for Mob-015	04-23
Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	04-08
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-13
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-13
Moberg Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
Moberg Pharma Announces Leadership Changes	11-07
Moberg Pharma AB Appoints Nomination Committee	23-10-17
Moberg Pharma Completes Patient Recruitment for North American Trial of Nail Fungus Treatment	23-10-06
Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America	23-10-06
Moberg Pharma to Issue New Units as Guarantors' Commission; Shares Falls 11%	23-09-08
Moberg Pharma Raises SEK100 Million in Oversubscribed Rights Issue; Shares Surge 22%	23-09-01
Moberg Pharma to Launch SEK100 Million Rights Offering	23-08-07
Moberg Pharma Surges 39% With Swedish Approval for Fungal Nail Infection Treatment	23-08-04
Moberg Pharma AB Announces National Approval for MOB-015 in Sweden	23-08-04
Moberg Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Moberg Pharma AB Announces That Mob-015 has Received National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults	23-07-31
Moberg Pharma AB Announces Approval for Mob-015 in the European Union	23-07-05
Moberg Pharma's Antifungal Medicine Backed for Approval in 13 EU Nations; Shares Tank 39%	23-06-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Moberg Pharma AB

Equities

MOB

SE0020353928

Other languages

Filters